MC GILL UNIVERSITY
In 2013, Domain Therapeutics, Université de Montréal, IRICoR and McGill University signed a licensing and partnership agreement on first generation of G Protein Coupled Receptor biosensor technology.
The bioSens-All™ technology was developed through a consortium led by Prof. Michel Bouvier and supported by the Quebec Consortium for Drug Discovery (CQDM). This technology aims at profiling the signaling signature of GPCRs biased ligands to discriminate the functional regulation of intracellular molecular pathways. Domain Therapeutics is granted with commercial rights to use bioSens-All™ primarily for its internal research, collaborations but also to propose access in fee-for service.
In 2016, Domain Therapeutics, Université de Montréal, IRICoR and McGill University signed a second licensing and partnership agreement on the second generation of G Protein Coupled Receptor biosensor technology (see press release).
This license completes the first license granted in 2013 to further expand the potential of the platform bioSens-All™ to profile signaling signature of biased ligands and more particularly the trafficking of GPCRs.